139 related articles for article (PubMed ID: 35532095)
21. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and biological evaluation of novel osimertinib derivatives as reversible EGFR kinase inhibitors.
Ding S; Gao Z; Hu Z; Qi R; Zheng X; Dong X; Zhang M; Shen J; Long T; Zhu Y; Tian L; Song W; Liu R; Li Y; Sun J; Duan W; Liu J; Chen Y
Eur J Med Chem; 2022 Aug; 238():114492. PubMed ID: 35696862
[TBL] [Abstract][Full Text] [Related]
23. Rational Computational Design of Fourth-Generation EGFR Inhibitors to Combat Drug-Resistant Non-Small Cell Lung Cancer.
Park H; Jung HY; Kim K; Kim M; Hong S
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33297461
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer.
Akazawa Y; Saito Y; Yoshikawa T; Saito K; Nosaka K; Shimomura M; Mizuno S; Nakamoto Y; Nakatsura T
Cancer Sci; 2020 Aug; 111(8):2736-2746. PubMed ID: 32391625
[TBL] [Abstract][Full Text] [Related]
25. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, and biological evaluation of novel quinoline derivatives as small molecule mutant EGFR inhibitors targeting resistance in NSCLC: In vitro screening and ADME predictions.
Kardile RA; Sarkate AP; Lokwani DK; Tiwari SV; Azad R; Thopate SR
Eur J Med Chem; 2023 Jan; 245(Pt 1):114889. PubMed ID: 36375337
[TBL] [Abstract][Full Text] [Related]
27. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
28. Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC).
Pawara R; Ahmad I; Nayak D; Wagh S; Wadkar A; Ansari A; Belamkar S; Surana S; Nath Kundu C; Patil C; Patel H
Bioorg Chem; 2021 Oct; 115():105234. PubMed ID: 34399322
[TBL] [Abstract][Full Text] [Related]
29. In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition.
Patel H; Pawara R; Surana S
Comput Biol Chem; 2018 Jun; 74():167-189. PubMed ID: 29627693
[TBL] [Abstract][Full Text] [Related]
30. Design, Synthesis and Biological Evaluation of the Quinazoline Derivatives as L858R/T790M/C797S Triple Mutant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Zhang M; Wang Y; Wang J; Liu Z; Shi J; Li M; Zhu Y; Wang S
Chem Pharm Bull (Tokyo); 2020; 68(10):971-980. PubMed ID: 32999149
[TBL] [Abstract][Full Text] [Related]
31. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
[TBL] [Abstract][Full Text] [Related]
32. Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S Triple Mutations: A Case Report.
Chen ZW; Lin G; Shih HJ; Wu CE
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614045
[TBL] [Abstract][Full Text] [Related]
33. Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors.
Doss GP; Rajith B; Chakraborty C; NagaSundaram N; Ali SK; Zhu H
Sci Rep; 2014 Aug; 4():5868. PubMed ID: 25091415
[TBL] [Abstract][Full Text] [Related]
34. Investigation of molecular mechanism leading to gefitinib and osimertinib resistance against EGFR tyrosine kinase: molecular dynamics and binding free energy calculation.
Singh A; Mishra A
J Biomol Struct Dyn; 2023 Jul; 41(10):4534-4548. PubMed ID: 35510318
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
Song Z; Huang S; Yu H; Jiang Y; Wang C; Meng Q; Shu X; Sun H; Liu K; Li Y; Ma X
Eur J Med Chem; 2017 Jun; 133():329-339. PubMed ID: 28395219
[TBL] [Abstract][Full Text] [Related]
36. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.
Rangachari D; To C; Shpilsky JE; VanderLaan PA; Kobayashi SS; Mushajiang M; Lau CJ; Paweletz CP; Oxnard GR; Jänne PA; Costa DB
J Thorac Oncol; 2019 Nov; 14(11):1995-2002. PubMed ID: 31377341
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and evaluation of the Brigatinib analogues as potent inhibitors against tertiary EGFR mutants (EGFR
Fang H; Wu Y; Xiao Q; He D; Zhou T; Liu W; Yang CH; Xie Y
Bioorg Med Chem Lett; 2022 Sep; 72():128729. PubMed ID: 35413415
[TBL] [Abstract][Full Text] [Related]
38. Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.
Planken S; Behenna DC; Nair SK; Johnson TO; Nagata A; Almaden C; Bailey S; Ballard TE; Bernier L; Cheng H; Cho-Schultz S; Dalvie D; Deal JG; Dinh DM; Edwards MP; Ferre RA; Gajiwala KS; Hemkens M; Kania RS; Kath JC; Matthews J; Murray BW; Niessen S; Orr ST; Pairish M; Sach NW; Shen H; Shi M; Solowiej J; Tran K; Tseng E; Vicini P; Wang Y; Weinrich SL; Zhou R; Zientek M; Liu L; Luo Y; Xin S; Zhang C; Lafontaine J
J Med Chem; 2017 Apr; 60(7):3002-3019. PubMed ID: 28287730
[TBL] [Abstract][Full Text] [Related]
39. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
Ou SI; Cui J; Schrock AB; Goldberg ME; Zhu VW; Albacker L; Stephens PJ; Miller VA; Ali SM
Lung Cancer; 2017 Jun; 108():228-231. PubMed ID: 28625641
[TBL] [Abstract][Full Text] [Related]
40. Psorachromene induces apoptosis and suppresses tumor growth in NSCLC cells harboring EGFR L858R/T790M/C797S.
Wang TH; Leu YL; Chen CC; Li HJ; Yang SC; Huang KY; Chen CY
Phytother Res; 2022 May; 36(5):2116-2126. PubMed ID: 35229911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
